Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) - PubMed (original) (raw)
Clinical Trial
. 1997 Jun 28;349(9069):1857-63.
- PMID: 9217756
Clinical Trial
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
No authors listed. Lancet. 1997.
Abstract
Background: In diabetic nephropathy, angiotensin-converting-enzyme (ACE) inhibitors have a greater effect than other antihypertensive drugs on proteinuria and the progressive decline in glomerular filtration rate (GFR). Whether this difference applies to progression of nondiabetic proteinuric nephropathies is not clear. The Ramipril Efficacy in Nephropathy study of chronic nondiabetic nephropathies aimed to address whether glomerular protein traffic influences renal-disease progression, and whether an ACE inhibitor was superior to conventional treatment, with the same blood-pressure control, in reducing proteinuria, limiting GFR decline, and preventing endstage renal disease.
Methods: In this prospective double-blind trial, 352 patients were classified according to baseline proteinuria (stratum 1: 1-3 g/24 h; stratum 2: > or = 3 g/24 h), and randomly assigned ramipril or placebo plus conventional antihypertensive therapy targeted at achieving diastolic blood pressure under 90 mm Hg. The primary endpoint was the rate of GFR decline. Analysis was by intention to treat.
Findings: At the second planned interim analysis, the difference in decline in GFR between the ramipril and placebo groups in stratum 2 was highly significant (p = 0.001). The Independent Adjudicating Panel therefore decided to open the randomisation code and do the final analysis in this stratum (stratum 1 continued in the trial). Data (at least three GFR measurements including baseline) were available for 56 ramipril-assigned patients and 61 placebo-assigned patients. The decline in GFR per month was significantly lower in the ramipril group than the placebo group (0.53 [0.08] vs 0.88 [0.13] mL/min, p = 0.03). Among the ramipril-assigned patients, percentage reduction in proteinuria was inversely correlated with decline in GFR (p = 0.035) and predicted the reduction in risk of doubling of baseline creatinine or endstage renal failure (18 ramipril vs 40 placebo, p = 0.04). The risk of progression was still significantly reduced after adjustment for changes in systolic (p = 0.04) and diastolic (p = 0.04) blood pressure, but not after adjustment for changes in proteinuria. Blood-pressure control and the overall number of cardiovascular events were similar in the two treatment groups.
Interpretation: In chronic nephropathies with proteinuria of 3 g or more per 24 h, ramipril safely reduces proteinuria and the rate of GFR decline to an extent that seems to exceed the reduction expected for the degree of blood-pressure lowering.
Comment in
- ACE-inhibitors: panacea for progressive renal disease.
Navis G, de Zeeuw D, de Jong PE. Navis G, et al. Lancet. 1997 Jun 28;349(9069):1852-3. doi: 10.1016/s0140-6736(97)22026-x. Lancet. 1997. PMID: 9217751 No abstract available. - Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study.
Krämer BK, Schweda F. Krämer BK, et al. Lancet. 1997 Sep 6;350(9079):736; author reply 736-7. doi: 10.1016/s0140-6736(97)26036-8. Lancet. 1997. PMID: 9291919 No abstract available. - Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study.
Porter AM. Porter AM. Lancet. 1997 Sep 6;350(9079):736; author reply 736-7. doi: 10.1016/s0140-6736(05)63539-8. Lancet. 1997. PMID: 9291920 No abstract available. - EUCLID study.
Tripathi K. Tripathi K. Lancet. 1997 Oct 11;350(9084):1102-3. doi: 10.1016/S0140-6736(05)70465-7. Lancet. 1997. PMID: 10213576 No abstract available.
Similar articles
- Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Ruggenenti P, et al. Kidney Int. 1998 May;53(5):1209-16. doi: 10.1046/j.1523-1755.1998.00874.x. Kidney Int. 1998. PMID: 9573535 Clinical Trial. - Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Ruggenenti P, et al. Lancet. 1999 Jul 31;354(9176):359-64. doi: 10.1016/S0140-6736(98)10363-X. Lancet. 1999. PMID: 10437863 Clinical Trial. - How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?
Pisoni R, Remuzzi G. Pisoni R, et al. J Nephrol. 2000 May-Jun;13(3):228-31. J Nephrol. 2000. PMID: 10928301 Review.
Cited by
- Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study.
Nihei S, Asaka J, Yaegashi M, Asahi K, Kudo K. Nihei S, et al. J Pharm Health Care Sci. 2024 Aug 23;10(1):51. doi: 10.1186/s40780-024-00372-8. J Pharm Health Care Sci. 2024. PMID: 39180119 Free PMC article. - The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?
Correa-Rotter R, Wheeler DC, McEwan P. Correa-Rotter R, et al. Adv Ther. 2024 Oct;41(10):3739-3748. doi: 10.1007/s12325-024-02950-6. Epub 2024 Aug 14. Adv Ther. 2024. PMID: 39141281 Free PMC article. Review. - Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases.
Alkaff FF, Lammerts RGM, Daha MR, Berger SP, van den Born J. Alkaff FF, et al. Clin Kidney J. 2024 Jul 10;17(8):sfae215. doi: 10.1093/ckj/sfae215. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39135935 Free PMC article. Review. - Atrial Fibrillation and Chronic Kidney Disease: Aetiology and Management.
Sidhu B, Mavilakandy A, Hull KL, Koev I, Vali Z, Burton JO, Ng GA. Sidhu B, et al. Rev Cardiovasc Med. 2024 Apr 9;25(4):143. doi: 10.31083/j.rcm2504143. eCollection 2024 Apr. Rev Cardiovasc Med. 2024. PMID: 39076563 Free PMC article. Review. - Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study.
Lamb EJ, Barratt J, Brettell EA, Cockwell P, Dalton RN, Deeks JJ, Eaglestone G, Pellatt-Higgins T, Kalra PA, Khunti K, Loud FC, Ottridge RS, Potter A, Rowe C, Scandrett K, Sitch AJ, Stevens PE, Sharpe CC, Shinkins B, Smith A, Sutton AJ, Taal MW. Lamb EJ, et al. Health Technol Assess. 2024 Jul;28(35):1-169. doi: 10.3310/HYHN1078. Health Technol Assess. 2024. PMID: 39056437 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous